Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (410)	2/25/1998 12:04:00 AM
From: Vector1	Read Replies (1) \| Respond to of 442

Mike, don't be ridiculous. This is a great offer for SMTG. It is a large premium over where the stock was trading before the leak and SMTG obviously could not find a partner willing to allow them to remain independent. The acquisition is also makes it more likely that a recomb blood substitiute will someday make it to the market since Baxter has the recources and apparent commitment to see it through. Look how much money they have spent on pushing through their own product which has a questionalble safety profile. Frankley I am surprised that Baxter did not buy Northfield which has a product closer to approval and competes against the Baxter product for outdated human blood as a raw material. V1